Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03361176 · ClinicalTrials.gov registry record · Phase 4

Kybella With Triamcinolone

A Phase 4 study of Adiposity, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
2
Study locations

NCT03361176 is a Phase 4 study of Adiposity that has completed, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 30 participants, below the 98-participant average among 11 other Adiposity trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03361176, a Phase 4 study of Adiposity, has completed, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This study is to evaluate the efficacy, edema and pain associated with Kybella(TM) injections of the upper neck in the treatment of submental fat with varying low concentrations of triamcinolone acetonide plus low doses of lidocaine.

Conditions Studied

Interventions

  • DRUG Injectable sodium deoxycholate
  • COMBINATION_PRODUCT Injectable sodium deoxycholate with Triamcinolone acetate

Study Locations (2)

California

  • West Dermatology Research Center - San Diego

Maryland

  • Maryland Dermatology Laser, Skin and Vein Institute - Hunt Valley

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-03-26
Est. Completion 2018-12-18
Phase Phase 4

What the Registry Record Tells You About NCT03361176

The ClinicalTrials.gov registry entry for NCT03361176 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 11 other Adiposity trials with a reported enrollment target (69% lower). The listed sponsor is Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Adiposity appearing as the primary indexed condition, and to 2 interventions - of which Injectable sodium deoxycholate is the first listed.

NCT03361176 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.

Frequently Asked Questions

What is clinical trial NCT03361176 about?

NCT03361176 is a clinical study titled "Kybella With Triamcinolone". This study is to evaluate the efficacy, edema and pain associated with Kybella(TM) injections of the upper neck in the treatment of submental fat with varying low concentrations of triamcinolone acetonide plus low doses of lidocaine.

What is the current status of trial NCT03361176?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2018-03-26. Estimated completion is 2018-12-18.

What conditions does trial NCT03361176 study?

This clinical trial studies the following conditions: Adiposity.

What interventions are being tested in trial NCT03361176?

The interventions under investigation include: Injectable sodium deoxycholate (DRUG), Injectable sodium deoxycholate with Triamcinolone acetate (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT03361176?

This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03361176 being conducted?

This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adiposity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.